nyuuzyou/wikis huggingface dataset:
Methylprednisolone (Solumedrol)

*Steroid conversions
==Diseases for which it is used==
*Immune thrombocytopenia (ITP)
*B-cell acute lymphoblastic leukemia
*Chronic lymphocytic leukemia
*CNS leukemia
*CNS lymphoma
*Diffuse large B-cell lymphoma
*Hemophagocytic lymphohistiocytosis
*Classical Hodgkin lymphoma
*Post-transplant lymphoproliferative disorder
*T-cell acute lymphoblastic leukemia
*Acquired thrombotic thrombocytopenic purpura
==Diseases for which it was used==
*Multiple myeloma
==History of changes in EMA indication==
*1957-12-18: EURD
==Also known as==
*Generic names: methylprednisolone acetate, methylprednisolone sodium succinate
*Brand names:
Synonyms 	Synonyms 	Synonyms 	Synonyms 	Synonyms 	Synonyms 	Synonyms 	Synonyms
Adlone 	Advantan 	Adventan 	Alergolon 	Amethapred 	Asmacortone 	Avancort 	Belon
Cortesa 	Cortisolona 	Decacort 	Depmedalone 	Depo-Medrate 	Depo-Medrol 	Depoject 	Depomedrone
Depo Melcort 	Depo Moderin 	Deposet 	Dispred 	Duralone 	Epizolone 	Excelin 	Hexilon
Indrol 	Intidrol 	Ivepred 	Lameson 	Lemod 	Lesol 	Lexcomet 	Lexxema
M-Prednihexal 	Medason 	Medirona 	Medisolu 	Medixon 	Medlin 	Medlone 	Mednin
Medralone 	Medrate 	Medrol 	Medrone 	Melon 	Melone 	Menisolon 	Menisone
Mepredron 	Meprolone Unipak	Meproson 	Mepsolone 	Mepson 	Mesolone 	Mesurin 	Methapred
Methisol 	Methybon 	Methylon 	Methylone 	Methylprednis 	Methylprednisolon	Methylprednisolonum	Methyran
Meticort 	Metidrol 	Metilbetasone	Metilprednisolona	Metilprednizolon-H	Metipred 	Metisone 	Metycortin
Metypred 	Metypresol 	Metysolon 	NEO-Drol 	Nirypan 	Phadilon 	Predisol 	Predmetil
Predni-M-Tablinen	Prednilem 	Predni M 	Prednol 	Prednol L 	Prednovare 	Prednox 	Pretilon
Pridol 	Promedrol 	Radilem 	Rumaxoi 	Salon H9C 	Sanexon 	SOL-Melcort 	Solocort-ACT
Solomet 	Solumedrol 	Solu Moderin 	Somelon 	Somerol 	Stenirol 	Succimed 	Supresol
Thimelon 	Tropidrol 	Unimedrol 	Urbason 	Vanderm 	Yumerole 	 	
Category:Drugs
Category:Intravenous medications
Category:Intrathecal medications
Category:Oral medications
Category:Immunosuppressants
Category:Steroids
Category:B-cell acute lymphoblastic leukemia medications
Category:Chronic lymphocytic leukemia medications
Category:CNS leukemia medications
Category:CNS lymphoma medications
Category:Diffuse large B-cell lymphoma medications
Category:Hemophagocytic lymphohistiocytosis medications
Category:Classical Hodgkin lymphoma medications
Category:Immune thrombocytopenia medications
Category:Post-transplant lymphoproliferative disorder ‎medications
Category:T-cell acute lymphoblastic leukemia medications
Category:Acquired thrombotic thrombocytopenic purpura medications
Category:Multiple myeloma medications (historic)
Category:FDA approved in 1957
Category:EMA approved in 1957
Category:WHO Essential Cancer Medicine
Metoclopramide (Reglan)

==General information==
Class/mechanism: Antiemetic; antiemetic action of metoclopramide is due to its antagonist activity at D2 receptors in the chemoreceptor trigger zone (CTZ)
Route: PO/IV
Extravasation: unknown
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
No known antineoplastic properties. Used for treatment and/or prevention of chemotherapy-induced nausea & vomiting.
==Also known as==
*Brand name: Reglan
Category:Drugs
Category:Oral medications
Category:Intravenous medications
Category:Emesis prevention
Category:Dopamine receptor antagonist
Category:FDA approved in 1980
Category:WHO Essential Pain and Palliative Care Medicine
Metronidazole (Flagyl)

==Mechanism of action==
Antibiotic which is a nitroimidazole.
==Diseases for which it is used==
*B-cell lymphoma of mucosa-associated lymphoid tissue
*Gastric DLBCL
==Also known as==
*Brand name: Flagyl
Category:Drugs
Category:Oral medications
Category:Intravenous medications
Category:Antibacterials
Category:Diffuse large B-cell lymphoma medications
Category:MALT lymphoma medications
Category:FDA approved in 1960
Mezigdomide (BMS-986348)

==Mechanism of action==
From the NCI Drug Dictionary: A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, mezigdomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces proteasome-mediated degradation of certain transcription factors, some of which are transcriptional repressors in T cells. This leads to modulation of the immune system, including activation of T lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types.
*IUPHAR/BPS
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Multiple myeloma===
#CC-92480-MM-001: Richardson PG, Trudel S, Popat R, Mateos MV, Vangsted AJ, Ramasamy K, Martinez-Lopez J, Quach H, Orlowski RZ, Arnao M, Lonial S, Karanes C, Pawlyn C, Kim K, Oriol A, Berdeja JG, Rodríguez Otero P, Casas-Avilés I, Spirli A, Poon J, Li S, Gong J, Wong L, Lamba M, Pierce DW, Amatangelo M, Peluso T, Maciag P, Katz J, Pourdehnad M, Bahlis NJ; CC-92480-MM-001 Study Investigators. Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Sep 14;389(11):1009-1022. Epub 2023 Aug 30. link to original article EuroPMC NCT03374085
==Also known as==
*Code names: BMS-986348, CC-92480
Category:Drugs
Category:Oral medications
Category:Cereblon E3 ubiquitin ligase modulators
Category:Multiple myeloma medications (investigational)
Category:Investigational drugs
Mifamurtide (Mepact)

==Mechanism of action==
Fully synthetic derivative of muramyl dipeptide (MDP)
==Diseases for which it is used==
*Osteosarcoma
==History of changes in EMA indication==
*2009-03: Initial marketing authorisation
==Also known as==
*Brand name: Mepact
Category:Drugs
Category:Intravenous medications
Category:Synthetic muramyl dipeptides
Category:Osteosarcoma medications
Category:EMA approved in 2009
Category:Stub
Miriplatin (Miripla)

Platinum agent used in TACE
==Diseases for which it is used==
*Hepatocellular carcinoma
==History of changes in PMDA indication==
*2009-10-16: Initial approval for lipiodolization in hepatocellular carcinoma.
==Also known as==
*Brand name: Miripla
Category:Drugs
Category:Intra-arterial medications
Category:Platinum agents
Category:Hepatocellular carcinoma medications
Category:PMDA approved in 2009
Category:Stub
Mirvetuximab soravtansine (Elahere)

==Mechanism of action==
From the NCI Drug Dictionary: An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent’s efficacy in multidrug resistant tumor cells.
==Diseases for which it is established==
*Ovarian cancer
==History of changes in FDA indication==
*2022-11-14: Granted accelerated approval for adult patients with folate receptor alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. (Based on SORAYA)
**2024-03-22: Regular approval for adult patients with folate receptor alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Patients are selected based on an FDA-approved test. (Based on MIRASOL)
==Also known as==
*Code name: IMGN-853
*Generic name: mirvetuximab soravtansine-gynx
*Brand name: Elahere
Category:Drugs
Category:Intravenous medications
Category:Protein expression-specific medications
Category:Anti-FOLR1 antibody-drug conjugates
Category:Microtubule inhibitors
Category:Ovarian cancer medications
Category:FDA approved in 2022
Mitapivat (Pyrukynd)

==Mechanism of action==
Pyruvate kinase activator
==Diseases for which it is used==
===Beta thalassemia===
#AG348-C-010: Kuo KHM, Layton DM, Lal A, Al-Samkari H, Bhatia J, Kosinski PA, Tong B, Lynch M, Uhlig K, Vichinsky EP. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study. Lancet. 2022 Aug 13;400(10351):493-501. link to original article EuroPMC NCT03692052
===Pyruvate kinase deficiency===
==History of changes in FDA indication==
*2022-02-17: Initial approval to treat hemolytic anemia (a disorder in which red blood cells are destroyed faster than they can be made) in adults with pyruvate kinase (PK) deficiency. (Based on ACTIVATE & ACTIVATE-T)
==Also known as==
*Code name: AG-348
*Brand name: Pyrukynd
Category:Drugs
Category:Oral medications
Category:Pyruvate kinase activator
Category:Beta thalassemia medications
Category:Pyruvate kinase deficiency medications
Category:FDA approved in 2022
Mitomycin (Mutamycin)

==General information==
Class/mechanism: Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. At higher concentrations, can also inhibit RNA and protein synthesis.Mitomycin (Mutamycin) package insert Mitomycin (Mutamycin) package insert (locally hosted backup)
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is used==
*Anal cancer
*Bladder cancer
*Breast cancer
*Cervical cancer
*Cholangiocarcinoma
*Colorectal cancer
*Esophageal cancer
**Esophageal adenocarcinoma
*Gallbladder cancer
*Gastric cancer
*Head and neck cancer
==Diseases for which is was used==
*Non-small cell lung cancer
*Pancreatic cancer
==Patient drug information==
*Mitomycin (Mutamycin) patient drug information (Chemocare)Mitomycin (Mutamycin) patient drug information (Chemocare)
*Mitomycin (Mutamycin) patient drug information (UpToDate)Mitomycin (Mutamycin) patient drug information (UpToDate)
==History of changes in FDA indication==
*1974: Initial FDA approval for use in gastric and pancreatic carcinomas when combined with other chemotherapeutic agents.
*Uncertain date: Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. (No supporting studies are cited)
==History of changes in EMA indication==
*1962-10-05: EURD
==Also known as==
*Generic names: mitomycin-C, MTC
*Brand names: Lyomit, Mitocin, Mitocyte, Mitosol, Mitozytrex, Mutamycin
==References==
Category:Drugs
Category:Intravenous medications
Category:Intravesical medications
Category:Vesicant
Category:Antitumor antibiotics
Category:Human DNA synthesis inhibitors
Category:Anal cancer medications
Category:Bladder cancer medications
Category:Breast cancer medications
Category:Cervical cancer medications
Category:Cholangiocarcinoma medications
Category:Colorectal cancer medications
Category:Esophageal adenocarcinoma medications
Category:Esophageal cancer medications
Category:Gallbladder cancer medications
Category:Gastric cancer medications
Category:Head and neck cancer medications
Category:Non-small cell lung cancer medications (historic)
Category:Pancreatic cancer medications (historic)
Category:FDA approved in 1974
Category:EMA approved in 1962
Mitomycin pyelocalyceal (Jelmyto)

==Mechanism of action==
Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. Formulated for pyelocalyceal infusion.
==Diseases for which it is used==
*Upper tract urothelial carcinoma
==History of changes in FDA indication==
*2020-04-15: Approved for adult patients with low-grade upper tract urothelial cancer (LG-UTUC). (Based on OLYMPUS)
==Also known as==
*Brand name: Jelmyto
Category:Drugs
Category:Intravesical medications
Category:Antitumor antibiotics
Category:Human DNA synthesis inhibitors
Category:Upper tract urothelial carcinoma medications
Category:FDA approved in 2020
Mitotane (Lysodren)

==General information==
Class/mechanism: Adrenal cytotoxic agent, suppresses adrenal cortex and the extra-adrenal metabolism of cortisol.Mitotane (Lysodren) package insert Mitotane (Lysodren) package insert (locally hosted backup)
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is used==
*Adrenocortical carcinoma
==Patient drug information==
*Mitotane (Lysodren) patient drug information (UpToDate)Mitotane (Lysodren) patient drug information (UpToDate)
==History of changes in FDA indication==
*1970-07-08: Approved for the treatment of inoperable, functional or nonfunctional, adrenal cortical carcinoma.
==History of changes in EMA indication==
*2004-04-28: Indicated for symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established. (No supporting studies are cited)
==Also known as==
*Generic name: o,p'-DDD
*Brand name: Lysodren
==References==
Category:Drugs
Category:Oral medications
Category:Adrenal suppressant
Category:Adrenocortical carcinoma medications
Category:FDA approved in 1970
Mobocertinib (Exkivity)

==Mechanism of action==
From the NCI Drug Dictionary: An orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineoplastic activity. Upon oral administration, mobocertinib, and its active metabolites, specifically and irreversibly binds to and inhibits exon 20 insertion mutations of EGFR. This prevents EGFR-mediated signaling and leads to cell death in tumor cells expressing exon 20 insertion mutations. In addition, mobocertinib may inhibit the activity of other EGFR family members, such as human epidermal growth factor receptor 2 (HER2; ERBB2) and HER4.
==Diseases for which it was used==
*EGFRm NSCLC
==History of changes in FDA indication==
* 2021-09-15: Granted accelerated approval for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. (Based on AP32788-15-101)
**2024-07-09: Drug withdrawn due to failure of confirmatory trial.
==Also known as==
*Code names: AP-32788, TAK-788
*Brand name: Exkivity
Category:Drugs
Category:Oral medications
Category:Mutation-specific medications
Category:EGFR inhibitors
Category:ERBB2 inhibitors
Category:ERBB4 inhibitors
Category:Non-small cell lung cancer medications (historic)
Category:FDA approved in 2021
Category:FDA withdrawn in 2024
Mocetinostat (MGCD-0103)

==Mechanism of action==
From the NCI Drug Dictionary: A rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activity. Mocetinostat binds to and inhibits Class 1 isoforms of HDAC, specifically HDAC 1, 2 and 3, which may result in epigenetic changes in tumor cells and so tumor cell death; although the exact mechanism has yet to be defined, tumor cell death may occur through the induction of apoptosis, differentiation, cell cycle arrest, inhibition of DNA repair, upregulation of tumor suppressors, down regulation of growth factors, oxidative stress, and autophagy, among others.
==Preliminary data==
===Classical Hodgkin lymphoma===
# Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J, Li Z, Drouin M, Patterson T, Ward MR, Paulus JK, Ji Y, Medeiros LJ, Martell RE. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2011 Dec;12(13):1222-8. Epub 2011 Oct 25. link to original article link to PMC article PubMed
==Also known as==
*Code name: MGCD-0103
Category:Drugs
Category:Oral medications
Category:HDAC inhibitors
Category:Classical Hodgkin lymphoma medications (investigational)
Category:Investigational drugs
Mogamulizumab (Poteligeo)

==Mechanism of action==
From the NCI Drug Dictionary: A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. Mogamulizumab (Poteligeo) package insert Mogamulizumab (Poteligeo) package insert (locally hosted backup)Poteligeo manufacturer's website
==Diseases for which it is used==
*Adult T-cell leukemia-lymphoma
*Cutaneous T-cell lymphoma
*Peripheral T-cell lymphoma
==History of changes in FDA indication==
*2018-08-08: Initial approval for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. (Based on MAVORIC)
==History of changes in EMA indication==
*2018-11-22: Initial authorization
==History of changes in Health Canada indication==
*2022-06-02: Initial notice of compliance for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. 
==History of changes in PMDA indication==
*2012-03-30: Initial approval for the treatment of recurrent or relapsed CCR4-positive adult T-cell leukemia/lymphoma.
*2014-03-17: New additional indications for the treatment of relapsed or refractory CCR4-positive peripheral T-cell lymphoma and relapsed or refractory CCR4-positive cutaneous T-cell lymphoma.
*2014-12-18: Revised indication and a new dosage for the treatment of CCR4-positive adult T-cell leukemia/lymphoma.
*2018-08-21: New indications and a new dosage for the treatment of relapsed or refractory cutaneous T-cell lymphoma.
==Also known as==
*Code name: KW-0761
*Generic name: mogamulizumab-kpkc
*Brand name: Poteligeo
==References==
Category:Drugs
Category:Intravenous medications
Category:Anti-CCR4 antibodies
Category:Anti-CD194 antibodies
Category:Adult T-cell leukemia-lymphoma medications
Category:Cutaneous T-cell lymphoma medications
Category:Peripheral T-cell lymphoma medications
Category:EMA approved in 2018
Category:FDA approved in 2018
Category:Health Canada approved in 2022
Category:PMDA approved in 2012
Momelotinib (Ojjaara)

==Mechanism of action==
From the NCI Drug Dictionary: An orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with potential antineoplastic activity. Momelotinib competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells.
*IUPHAR/BPS
==Diseases for which it is established==
*Myelofibrosis
==History of changes in FDA indication==
*2023-09-15: Approved for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. (Based on MOMENTUM & SIMPLIFY-1)
==History of changes in EMA indication==
*2024-01-24: Initial authorization as Omjjara. Omjjara is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naive or have been treated with ruxolitinib. (Based on MOMENTUM & SIMPLIFY-1)
==Also known as==
*Code names: CYT-387, GS-0387
*Brand name: Ojjaara, Omjjara
Category:Drugs
Category:Oral medications
Category:ACVR1 inhibitors
Category:JAK1 inhibitors
Category:JAK2 inhibitors
Category:JAK3 inhibitors
Category:TYK2 inhibitors
Category:Myelofibrosis medications
Category:FDA approved in 2023
Category:EMA approved in 2024
Montelukast (Singulair)

Sometimes used in hypersensitivity protocols or as a premedication for antineoplastics highly likely to provoke and allergic reaction. Also used as a preventative medication for mast cell diseases.
==Also known as==
*Brand names: Alecast, Monkast, Montair, Plenair, Singulair
Category:Drugs
Category:Oral medications
Category:Antileukotrienes
Category:FDA approved in 2003
Mosunetuzumab (Lunsumio)

==Mechanism of action==
From the NCI Drug Dictionary: A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Anti-CD20-CD3 bispecific monoclonal antibody BTCT4465A contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, BTCT4465A binds to both T cells and CD20-expressing tumor B cells; this cross-links T cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells.
==Diseases for which it is used==
*Follicular lymphoma
==History of changes in FDA indication==
*2022-12-22: Initial approval for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. (Based on GO29781)
==History of changes in EMA indication==
*2022-06-03: Initial conditional authorization as monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies. (Based on GO29781)
==Also known as==
*Code names: BTCT-4465A, RG-7828
*Generic name: mosunetuzumab-axgb
*Brand name: Lunsumio
Category:Drugs
Category:Intravenous medications
Category:Anti-CD20-CD3 bispecific antibodies
Category:Follicular lymphoma medications
Category:EMA approved in 2022
Category:FDA approved in 2022